CEO Dave Ricks said Lilly is now considering expanding the vial offering. “We’d like to lower the entry cost and we’d like to have more doses available. That’s not something we’re ...

While neither a positive nor a negative for Lilly, it also means that first-to-market Novo Nordisk didn't lose market share in the quarter, and I'd consider this a positive for that stock ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...